Bromperidol | CAS#10457-90-6 | Long-Acting Neuroleptic

Bromperidol
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329215

CAS#: 10457-90-6

Description: Bromperidol, also known as Impromen and R-11333, is used as a means of long-term maintenance treatment of schizophrenia. Bromperidol is a close structural analogue of haloperidol. Bromperidol is a butyrophenone derivative. It is a potent and long-acting neuroleptic.

Chemical Structure

Bromperidol

CAS# 10457-90-6

Instruction

Theoretical Analysis

MedKoo Cat#: 329215
Name: Bromperidol
CAS#: 10457-90-6
Chemical Formula: C21H23BrFNO2
Exact Mass: 419.09
Molecular Weight: 420.322
Elemental Analysis: C, 60.01; H, 5.52; Br, 19.01; F, 4.52; N, 3.33; O, 7.61

Price and Availability

Size	Price	Availability
100mg	USD 950	2 Weeks
200mg	USD 1650	2 Weeks
500mg	USD 2650	2 Weeks
1g	USD 3650	2 Weeks
2g	USD 6450	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Bromperidol; R-11333; R 11333; R11333; Impromen; Bromidol, Bromodol;

IUPAC/Chemical Name: 4-(4-(4-bromophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one

InChi Key: RKLNONIVDFXQRX-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H23BrFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

SMILES Code: O=C(C1=CC=C(F)C=C1)CCCN2CCC(O)(C3=CC=C(Br)C=C3)CC2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 420.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD001719. doi: 10.1002/14651858.CD001719.pub4. PMID: 23152208; PMCID: PMC7061326.

2: Purgato M, Adams CE. Bromperidol decanoate (depot) for schizophrenia. Cochrane Database Syst Rev. 2011 Sep 7;(9):CD001719. doi: 10.1002/14651858.CD001719.pub3. Update in: Cochrane Database Syst Rev. 2012;11:CD001719. PMID: 21901678.

3: Benfield P, Ward A, Clark BG, Jue SG. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses. Drugs. 1988 Jun;35(6):670-84. doi: 10.2165/00003495-198835060-00004. PMID: 3048975.

4: Wong D, Adams CE, David A, Quraishi SN. Depot bromperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2004;(3):CD001719. doi: 10.1002/14651858.CD001719.pub2. Update in: Cochrane Database Syst Rev. 2011;(9):CD001719. PMID: 15266450.

5: Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol. 2014;9(3):310-7. doi: 10.2174/15748847113089990051. PMID: 23343447.

6: Quraishi S, David A, Adams CE. Depot bromperidol decanoate for schizophrenia. Cochrane Database Syst Rev. 2000;(2):CD001719. doi: 10.1002/14651858.CD001719. Update in: Cochrane Database Syst Rev. 2004;(3):CD001719. PMID: 10796447.

7: Tischio J, Hetyei N, Patrick J. Bromperidol radioimmunoassay: human plasma levels. J Pharm Sci. 1984 Apr;73(4):546-8. doi: 10.1002/jps.2600730428. PMID: 6726642.

8: Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y, Shibata M, Ikeda K. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit. 1997 Jun;19(3):261-4. doi: 10.1097/00007691-199706000-00003. PMID: 9200764.

9: Sato S, Someya T, Shioiri O, Koitabashi T, Inoue Y. Involvement of CYP3A4 in the metabolism of bromperidol in vitro. Pharmacol Toxicol. 2000 Mar;86(3):145-8. doi: 10.1034/j.1600-0773.2000.d01-27.x. PMID: 10752674.

10: Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Furukori H, Kaneko S, Inoue Y. Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol. 1997;52(3):219-22. doi: 10.1007/s002280050277. PMID: 9218929.

11: Ostuzzi G, Bertolini F, Del Giovane C, Tedeschi F, Bovo C, Gastaldon C, Nosé M, Ogheri F, Papola D, Purgato M, Turrini G, Correll CU, Barbui C. Maintenance Treatment With Long-Acting Injectable Antipsychotics for People With Nonaffective Psychoses: A Network Meta-Analysis. Am J Psychiatry. 2021 May 1;178(5):424-436. doi: 10.1176/appi.ajp.2020.20071120. Epub 2021 Feb 18. PMID: 33596679.

12: Dubinsky B, McGuire JL, Niemegeers CJ, Janssen PA, Weintraub HS, McKenzie BE. Bromperidol, a new butyrophenone neuroleptic: a review. Psychopharmacology (Berl). 1982;78(1):1-7. doi: 10.1007/BF00470578. PMID: 6128755.

13: Suzuki A, Otani K, Mihara K, Yasui N, Kondo T, Tokinaga N, Furukori H, Kaneko S, Inoue Y, Hayashi K. Effects of various factors including the CYP2D6 genotype and coadministration of flunitrazepam on the steady-state plasma concentrations of bromperidol and its reduced metabolite. Psychopharmacology (Berl). 1998 Feb;135(4):333-7. doi: 10.1007/s002130050519. PMID: 9539256.

14: Yasui N, Otani K, Kondo T, Suzuki A, Furukori H, Kaneko S, Inoue Y. Correlation between steady-state plasma concentrations (Css) of bromperidol and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Apr;22(3):485-92. doi: 10.1016/s0278-5846(98)00019-0. PMID: 9612845.

15: Wong FA, Bateman CP, Shaw CJ, Patrick JE. Biotransformation of bromperidol in rat, dog, and man. Drug Metab Dispos. 1983 Jul-Aug;11(4):301-7. PMID: 6137334.

16: Yasui-Furukori N, Kondo T, Suzuki A, Mihara K, Kaneko S, Otani K. Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):575-8. doi: 10.1016/s0278-5846(01)00310-4. PMID: 11999910.

17: Mihara K, Otani K, Yasui N, Ishida M, Kondo T, Suzuki A, Furukori H, Nagashima U, Kaneko S, Inoue Y. No pharmacokinetic but pharmacodynamic interactions between cisapride and bromperidol or haloperidol. Ther Drug Monit. 1999 Jun;21(3):297-300. doi: 10.1097/00007691-199906000-00007. PMID: 10365640.

18: Furukori H, Kondo T, Yasui N, Otani K, Tokinaga N, Nagashima U, Kaneko S, Inoue Y. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology (Berl). 1999 Jul;145(2):189-92. doi: 10.1007/s002130051048. PMID: 10463320.

19: Suzuki A, Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Kaneko S, Inoue Y. No interaction between desipramine and bromperidol. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct;20(7):1265-71. doi: 10.1016/s0278-5846(96)00111-x. PMID: 8938825.

20: Otani K, Ishida M, Yasui N, Kondo T, Mihara K, Suzuki A, Kaneko S, Inoue Y, Shibata M, Ikeda K. No effect of the anticholinergic drugs trihexyphenidyl and biperiden on the plasma concentrations of bromperidol and its reduced metabolite. Ther Drug Monit. 1997 Apr;19(2):165-8. doi: 10.1097/00007691-199704000-00008. PMID: 9108644.

Your view history

Bromperidol featured